Programs & Expertise

LinusBio Precision Exposome Medicine Program Follows The Evolving Precision Medicine Paradigm

LinusBio is developing and commercializing hair strand tests for complex health conditions.

A substantial need exists for new biomarkers, especially for CNS conditions and GI disorders caused by the interplay of genetics and the environment. Extensive research in these areas has yet to result in genetic tests to guide diagnosis and treatment choices. Without biological tests, doctors continue to rely on questionnaires and specialists’ observations of symptoms for their clinical decision-making.

Our goal is to bring precision exposome medicine to patients with autism, ADHD, schizophrenia, ALS, irritable bowel syndrome, and other complex conditions lacking biomarkers with evidence of clinical utility.

Imagine if a lab test:

We are working to make this vision a reality. Temporal exposomic sequencing has the potential to transform how complex disorders are diagnosed and treated. Our tests might identify conditions before symptoms appear, aid in diagnosing and monitoring the progression of health conditions, serve as objective molecular endpoints in clinical trials, characterize the response to treatment, and more.

Disorder Type Disorder Patent & PCT Submitted Clinical & Epid. Studies Pathway Characterization Current Status
CNS 1001 – Early Autism Detection FDA Breakthrough Designation granted
CNS 1002 – Attention Deficit Hyperactive Disorder Enrollment ongoing
CNS 1003 — Psychosis & schizophrenia Enrollment ongoing
CNS 1004 – Lou Gehrig’s Disease FDA submission Q2 2022
Gut IBS, Eosinophilic Esophagitis, Microbiome Enrollment ongoing
Cancer Pediatric Cancer Enrollment ongoing
Data Science Global biodynamics dataset Prototype complete


LinusBio Precision Exposome Medicine Program Follows The Evolving Precision Medicine Paradigm:

Near-Future Deliverables For Neurodevelopmental Disease:

Milestone Collaborations Achieved On Two Fronts:

Next Breakthrough Programs: